Moderna’s experimental mRNA cancer treatment progresses, shares spike - National | Globalnews.ca
Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine designed to be tailored to individual patients based on unique mutations within their tumors.
Ähnliche Seiten
Moderna shares climb over 110% as mRNA vaccine with Merck succeeds in large trial for skin cancer | Stock Market News